Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642182 · ClinicalTrials.gov registry record · Phase 1
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
A Phase 1 study of Psoriasis, sponsored by SFA Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 3
- Study locations
NCT05642182: Recruiting Phase 1 study of Psoriasis, sponsored by SFA Therapeutics.
NCT05642182 is a Phase 1 study of Psoriasis that is actively recruiting participants, run by SFA Therapeutics. The registered enrollment target is 90 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05642182, a Phase 1 study of Psoriasis, is actively recruiting participants, sponsored by SFA Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.
Primary Outcome
+/- % Change in Psoriasis (PASI) index from baseline measurement at first dose
Conditions Studied
Interventions
- DRUG SFA002
Study Locations (3)
Florida
- NuLine Clinical Trial Center - Pompano Beach
North Dakota
- Axis Clincals USA/ Red River Research Patners. LLC - Fargo
Pennsylvania
- Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 1 |
What NCT05642182 shows while recruiting
NCT05642182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which SFA002 is the first listed.
NCT05642182 reports a single indexed study location in Florida, North Dakota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05642182 about?
NCT05642182 is a clinical study titled "Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques". The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed...
What is the current status of trial NCT05642182?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-03-31. Estimated completion is 2025-07-31.
What conditions does trial NCT05642182 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05642182?
The interventions under investigation include: SFA002 (DRUG).
Who is sponsoring clinical trial NCT05642182?
This trial is sponsored by SFA Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642182 being conducted?
This trial has 3 study locations across Florida, North Dakota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05642182's enrollment target sits among peer trials
90 61st of 125 higher than 65 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI